525 related articles for article (PubMed ID: 33030550)
41. Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study.
Maschmeyer G; Heinz WJ; Hertenstein B; Horst HA; Requadt C; Wagner T; Cornely OA; Löffler J; Ruhnke M;
Eur J Clin Microbiol Infect Dis; 2013 May; 32(5):679-89. PubMed ID: 23271674
[TBL] [Abstract][Full Text] [Related]
42. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation.
Döring M; Müller C; Johann PD; Erbacher A; Kimmig A; Schwarze CP; Lang P; Handgretinger R; Müller I
BMC Infect Dis; 2012 Oct; 12():263. PubMed ID: 23082876
[TBL] [Abstract][Full Text] [Related]
43. Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.
Marks DI; Liu Q; Slavin M
Expert Rev Anti Infect Ther; 2017 May; 15(5):493-502. PubMed ID: 28335642
[TBL] [Abstract][Full Text] [Related]
44. Risk factors for invasive fungal infections after haematopoietic stem cell transplantation: a systematic review and meta-analysis.
Biyun L; Yahui H; Yuanfang L; Xifeng G; Dao W
Clin Microbiol Infect; 2024 May; 30(5):601-610. PubMed ID: 38280518
[TBL] [Abstract][Full Text] [Related]
45. Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.
McCoy D; Depestel DD; Carver PL
Pharmacotherapy; 2009 Nov; 29(11):1306-25. PubMed ID: 19857148
[TBL] [Abstract][Full Text] [Related]
46. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
Solano C; Slavin M; Shaul AJ; Marks DI; Cordonnier C; Cornely OA; Pagliuca A; Cragin L; Jarque I; Garcia-Vidal C; Sorensen S; Vanness DJ; Charbonneau C; Barrueta JA; Peral C; De Salas-Cansado M; Bow EJ
Mycoses; 2017 Feb; 60(2):79-88. PubMed ID: 27562016
[TBL] [Abstract][Full Text] [Related]
47. Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation.
Rosillo C; Avila AM; Huang YT; Devlin S; Cho C; Montoro J; Maloy MA; Papanicolaou GA; Barba P; Perales MA
Transpl Infect Dis; 2018 Aug; 20(4):e12897. PubMed ID: 29668073
[TBL] [Abstract][Full Text] [Related]
48. The cost-utility analysis of antifungal prophylaxis for invasive fungal infections in acute myeloid leukaemia patients receiving chemotherapy: a study from a middle-income country.
Pungprasert T; Dhirachaikulpanich D; Phutthasakda W; Tantai N; Maneeon S; Nganthavee V; Atipas K; Tanpong S; Krithin S; Tanglitanon S; Jutidamrongphan W; Chayakulkeeree M; Srinonprasert V; Phikulsod P
J Hosp Infect; 2024 Mar; 145():118-128. PubMed ID: 38219835
[TBL] [Abstract][Full Text] [Related]
49. [Is micafungin useful in the prophylaxis of invasive fungal disease in hematological patients?].
Salavert M; Jarque I
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():43-9. PubMed ID: 21420577
[TBL] [Abstract][Full Text] [Related]
50. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation.
Chaftari AM; Hachem RY; Ramos E; Kassis C; Campo M; Jiang Y; Prince RA; Wang W; Raad II
Transplantation; 2012 Aug; 94(3):302-8. PubMed ID: 22814329
[TBL] [Abstract][Full Text] [Related]
51. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.
Maertens JA; Rahav G; Lee DG; Ponce-de-León A; Ramírez Sánchez IC; Klimko N; Sonet A; Haider S; Diego Vélez J; Raad I; Koh LP; Karthaus M; Zhou J; Ben-Ami R; Motyl MR; Han S; Grandhi A; Waskin H;
Lancet; 2021 Feb; 397(10273):499-509. PubMed ID: 33549194
[TBL] [Abstract][Full Text] [Related]
52. Compare the efficacy of antifungal agents as primary therapy for invasive aspergillosis: a network meta-analysis.
Liu A; Xiong L; Wang L; Zhuang H; Gan X; Zou M; Wang X
BMC Infect Dis; 2024 Jun; 24(1):581. PubMed ID: 38867163
[TBL] [Abstract][Full Text] [Related]
53. Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.
Girmenia C; Frustaci AM; Gentile G; Minotti C; Cartoni C; Capria S; Trisolini SM; Matturro A; Loglisci G; Latagliata R; Breccia M; Meloni G; Alimena G; Foà R; Micozzi A
Haematologica; 2012 Apr; 97(4):560-7. PubMed ID: 22102706
[TBL] [Abstract][Full Text] [Related]
54. Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison.
Tormo M; Pérez-Martínez A; Calabuig M; Hernández-Boluda JC; Amat P; Navarro D; Solano C
Mycoses; 2018 Mar; 61(3):206-212. PubMed ID: 29125660
[TBL] [Abstract][Full Text] [Related]
55. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.
Vehreschild MJ; von Bergwelt-Baildon M; Tran L; Shimabukuro-Vornhagen A; Wisplinghoff H; Bangard C; Cornely OA; Vehreschild JJ
Eur J Haematol; 2014 Nov; 93(5):400-6. PubMed ID: 24798021
[TBL] [Abstract][Full Text] [Related]
56. Antifungal agents for preventing fungal infections in solid organ transplant recipients.
Playford EG; Webster AC; Sorell TC; Craig JC
Cochrane Database Syst Rev; 2004; (3):CD004291. PubMed ID: 15266524
[TBL] [Abstract][Full Text] [Related]
57. Posaconazole: an oral triazole with an extended spectrum of activity.
Rachwalski EJ; Wieczorkiewicz JT; Scheetz MH
Ann Pharmacother; 2008 Oct; 42(10):1429-38. PubMed ID: 18713852
[TBL] [Abstract][Full Text] [Related]
58. Complications of hematopoietic stem transplantation: Fungal infections.
Omrani AS; Almaghrabi RS
Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):239-244. PubMed ID: 28636889
[TBL] [Abstract][Full Text] [Related]
59. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
[TBL] [Abstract][Full Text] [Related]
60. Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections.
Clark NM; Grim SA; Lynch JP
Semin Respir Crit Care Med; 2015 Oct; 36(5):767-85. PubMed ID: 26398542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
